Sponsored by Sanofi on May 22, 2022 Dolivi® (clopidogrel aspirin tablets) China launch event kicks off! The meeting specially invited Academician Ge Junbo of Zhongshan Hospital Affiliated to Fudan University, Professor Huo Yong of Peking University First Hospital, and Professor Chen Jiyan of Guangdong Provincial People’s Hospital as the chairman of the conference, and brought together front-line experts in the cardiovascular field at home and abroad to gather in the cloud to discuss acute coronary syndrome ( ACS) management strategy and the application advantages of innovative single-piece compound preparations (SPC), open a new perspective of ACS treatment plan!
>Looking forward: DOLVI® Opening a new pattern of ACS dual antiplatelet cornerstone therapy
Fig. 1. Dolidimensional® Sexuality and compliance, patients benefit moreDolivit®< /span>The efficacy and safety of the treatment were not inferior to single-agent combination therapy. The bioequivalence study showed that the clopidogrel/aspirin SPC and any single drug combination therapy had similar pharmacokinetic (PK) curves, and the PK parameters reached the bioequivalence standard in a better range, and were well tolerated and safe Sex results are similar³. The ACCEL-COMBO trial confirmed⁴ that P2Y12 response units during clopidogrel/aspirin SPC treatment were noninferior to monotherapy. In addition, two studies from France⁵ and Italy⁶ confirmed that compared with aspirin+clopidogrel monotherapy in SPC with clopidogrel/aspirin Adherence to treatment of ACS patients was higher. At the same time, clopidogrel/aspirin SPC is one tablet per day, which is convenient to administer, reduces the patient’s medication burden and treatment cost, and further improves the patient’s treatment compliance to achieve overall clinical benefits (Figure 1). Tough and far: Dolivi®is an optimal strategy for ACS antithrombotic therapy
pan® In adult patients already on concomitant clopidogrel and aspirin, it may also be used as a switch from clopidogrel and aspirin in the following two situations⁷:
▪ Non-ST Segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including stented patients after percutaneous coronary intervention.
▪ Medication use Patients with ST-segment elevation acute myocardial infarction suitable for thrombolysis.Zhongshan Hospital Affiliated to Fudan University Professor Zhang Shuning suggested that patients with coronary heart disease should start directly after loading dose therapy SPC, and long-term use. “Chinese Expert Consensus on Antiplatelet Therapy with Clopidogrel/Aspirin Single Tablet Compound Preparation” pointed out that, SPC can be used after the initial loading dose in the perioperative period, and routine maintenance 12 months, depending on the patient’s bleeding risk.⁸ (Figure 2).
Figure 2. SPC treatment pathway in ACS patientsIn addition, for patients starting ticagrelor + aspirin, if there is a ticagrelor-related Adverse reactions, such as dyspnea, can be passively (reactive) downgraded by DAPT and converted to clopidogrel/aspirin SPC (1 tablet per day); to prevent ticagrelor-related adverse reactions, it can also be active at 1 month (Prophylactic) DAPT downgrade. Stomach Love Guardian:Innovative “chip-in-chip” to prevent gastrointestinal bleeding strong>
Renji Hospital Affiliated to Shanghai Jiaotong UniversityProfessor Lu Hong To explore the management of gastrointestinal bleeding after PCI in patients with ACS, and to provide countermeasures to prevent bleeding. She pointed out that after PCI in patients with acute coronary syndrome, gastrointestinal bleeding is the most common type of bleeding, and continuous use of low-dose aspirin is one of the risk factors for gastrointestinal bleeding. To prevent gastrointestinal bleeding, the risk of bleeding and ischemia should be weighed, and antithrombotic drugs should be managed individually; secondly, the treatment strategy should be adjusted in time for patients with high bleeding risk. DOLVI®adopted Innovative “tablet-in-tablet” dosage form, the aspirin tablet is located in the core of the tablet, so that it is not exposed in the stomach, thereby preventing gastrointestinal adverse reactions caused by aspirin. In vitro experiments confirmed that aspirin did not dissolve in a simulated gastric environment⁷. Phase I bioequivalence study showed that ³, taking clopidogrel-aspirin SPC on an empty stomach had no adverse reactions; taking clopidogrel-aspirin SPC after meals, only 0.6% of the subjects had adverse reactions response, and only manifested as diarrhea (Figure 3).
Test preparation: clopidogrel + aspirin 100mg SPC (75mg enteric-coated clopidogrel) 100mg tablets and 75mg clopidogrel sulfate tablets were administered simultaneously
Figure 3. Dolivit was taken on an empty stomach and after meals, and the safety remained goodSummary
Academician Ge Junbo made a summary of the meeting. He pointed out that the East Asian population has a higher risk of bleeding than the Western population, and clopidogrel combined with aspirin is a reasonable DAPT option for antiplatelet therapy after ACS. The innovative “tablet-in-tablet” dosage form of clopidogrel/aspirin SPC has higher compliance, better safety, and the curative effect is not inferior to single-agent combination therapy, providing more options for antithrombotic therapy for ACS patients after PCI, opening dual A new era of combined antiplatelet therapy!
References:
1. Ma SC, et al. Adv Ther. 2020 Jul;37(7): 3150-3161 .2. Yong H, et al. Science Bulletin 2019; 64: 166–179.3. Wang L, et al. Adv Ther 2020; 37(6): 2696-27094. Koh JS, et al. Platelets 2017; 28(2): 187-193.5. Deharo P, et al. Int J Cardiol 2014; 172(1): e1-e2 .6. Maggioni AP, et al. Eur Heart J Acute Cardiovasc Care 2019; 8(6): 527-535.7. Chlorine Instructions for pidogrel-aspirin tablets. Approval date: September 30, 2021.8. Chinese Medical Doctor Association Cardiovascular Branch. Chinese Journal of Interventional Cardiology. 2021, 29(6): 306- 312.MAT-CN-2209835